Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331284

Institution ID

3331284

Institution full name and acronym

Research in Real Life

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A real-life historic study assessing metabolic and other adverse effects of small versus large particle inhaled corticosteroids in relation to their clinical benefit in obstructive lung disease
A RETROSPECTIVE, REAL-LIFE EVALUATION OF THE CARDIOVASCULAR DISEASE RISK ASSOCIATED WITH EXPOSURE TO PHARMACOLOGICAL SMOKING CESSATION INTERVENTIONS IN A REPRESENTATIVE UK PRIMARY CARE PATIENT POPULATION
Characterising patients at risk of failed Diskus use in primary care
Comparative effectiveness and safety of Ipramol (ipratropium/albuterol) SteriNebs® vs. DuoNeb®
Effectiveness of prescribing similar vs dissimilar devices for COPD management (phase 1)
Evaluation of patients with chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) who would benefit from aclidinium bromide treatment
Exploratory study identifying the benefits of pMDI versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary disease (COPD)
Increasing ICS Dose vs Add-on Therapy in Children with Asthma (Paediatric Asthma Step-up)
Metabolic effects associated with ICS (inhaled corticosteroid) use in COPD (chronic obstructive pulmonary disease) patients with type II diabetes
Predictors of treatment choice in patients with COPD
Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population - Phase 1 (Real-life effectiveness of Flutiform® Phase 1)
Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population – Phase 2 (Real-life effectiveness of Flutiform - Phase 2)
Real-life effectiveness evaluation of the long-acting muscarinic antagonist aclidinium bromide (Eklira®) for the management of COPD in a routine UK primary care population - Study 1 (Real-life acceptability of Eklira)
Real-world effectiveness of extrafine vesrus standard particle inhaled corticosteroids: A comparative effectiveness analysis of extrafine (EF) hydrofluoroalkane beclometasone (HFA-BDP) and Ciclesonide versus commonly prescribed standard particle inhaled corticosteroids for patients prescribed asthma therapy in The Netherlands (Extrafine vesrus stand particle ICS effectiveness)
State of the Union: Current asthma morbidity in the UK
THE RELIABILITY AND UTILITY OF BLOOD EOSINOPHILS AS A MARKER OF DISEASE BURDEN, HEALTHCARE RESOURCE UTILISATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (BLOOD EOSINOPHIL COUNT AND COPD)
Using real-life patient records to help identify predictors of future exacerbation risk (Asthma risk predictors)
Validation of real-life asthma research endpoints (Real-life asthma endpoint validation)